US Encouraging Monkeypox Vaccine Maker To Work With Large Pharma To Up Supply
The US FDA's Peter Marks also says the intradermal dose-sparing plan was motivated by concern over city and state one-dose strategies.
You may also be interested in...
Labeling changes for the pain products remain in active discussion, the US FDA commissioner tells the Senate Health, Education, Labor and Pensions Committee during a hearing on the monkeypox outbreak.
While Moderna plans preclinical studies and Tonix Pharma’s candidate is to enter trials in H1, Bavarian Nordic is seeking US and Indian manufacturing partners for its approved monkeypox vaccine. Scrip examines if the disease presents an opportunity for vaccine makers, like COVID-19 did or it could go the H1N1 way
The National Institutes of Health is gearing up to launch a trial that would test a smaller intradermal dose of Jynneos than was recently given an emergency use authorization, which could double vaccine supplies relative to currently available intradermal dosing. The trial still will leave the efficacy question unanswered.